JPM 2022: Abiomed, Penumbra, Renalityx
Executive Summary
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the fourth day of the meeting.
You may also be interested in...
Renalytix Collaborates With ADA To Improve Early Detection Of Kidney Disease
The American Diabetes Association and Renalytix will develop a comprehensive interprofessional risk-informed Diabetes Kidney Care Pathway and Model for optimal clinical treatment and risk reduction that can be applied nationally.
Cardiovascular Catch-Up: Abbott, Medtronic, Boston Scientific Stay Hot During Summer
June, July and August brought a number of important new approvals and trial announcements from the major cardiac device companies. Here are some of the highlights you might have missed during the summer.
Renalytix AI And AstraZeneca Collaborate To Improve Chronic Kidney Disease Outcomes
The companies will launch "precision medicine strategies" for chronic disease that use Renalytix' AI-enabled IVDs.